	US 12,480,127 B2
	siRNA, medical compositions, and methods for treating diabetes using the same
Liangyi Chen, Beijing (CN); Wenzhen Zhu, Beijing (CN); and Yi Wang, Beijing (CN)
Assigned to PEKING UNIVERSITY, Beijing (CN)
Filed by PEKING UNIVERSITY, Beijing (CN)
Filed on Jul. 26, 2023, as Appl. No. 18/359,858.
Application 18/359,858 is a continuation of application No. 17/663,826, filed on May 17, 2022, granted, now 11,746,350.
Application 17/663,826 is a continuation of application No. PCT/CN2021/086127, filed on Apr. 9, 2021.
Prior Publication US 2023/0383299 A1, Nov. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61P 3/10 (2006.01); C12N 15/11 (2006.01)

CPC C12N 15/1137 (2013.01) [A61K 31/713 (2013.01); A61P 3/10 (2018.01); C12N 15/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3521 (2013.01)]

11 Claims

1. A short interfering RNA (siRNA) molecule comprising a sense RNA strand and an anti-sense RNA strand, the sense and anti-sense RNA strands forming an RNA duplex, and wherein

the sense RNA strand or the anti-sense RNA strand is 15 to 25 nucleotides in length;

the sense RNA strand or the anti-sense RNA strand are 70%-100% complementary to a part of a nucleotide sequence of Ugt2b1 gene; and

the sense RNA strand has a nucleotide sequence having at least 92% similarity with SEQ ID NO. 1, and the anti-sense RNA strand has a nucleotide sequence having at least 92% similarity with SEQ ID NO. 2; or

the sense RNA strand has a nucleotide sequence having at least 92% similarity with SEQ ID NO. 3, and the anti-sense RNA strand has a nucleotide sequence having at least 92% similarity with SEQ ID NO. 4;

	SEQ ID NO. 1:
	5′-GGUUACUGUAGUUCACAAA-3′;

	SEQ ID NO. 2:
	5′-UUUGUGAACUACAGUAACCUC-3′;

	SEQ ID NO. 3:
	5′-GGACUUUGAUACAAUGUCA-3′;

	SEQ ID NO. 4:
	5′-UGACAUUGUAUCAAAGUCCAC-3′.